Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.101.20
- VernacularTitle:G719X/L861Q/S768I突变非小细胞肺癌诊断及靶向治疗进展
- Author:
WANG YUFANG
1
;
ZHENG JING
;
ZHU YANPING
;
ZHOU JIANYA
Author Information
1. 310000 杭州,浙江大学医学院附属第一医院呼吸与危重症医学科
- Keywords:
Lung neoplasms;
Epidermal growth factor receptor;
Major rare mutations;
Targeted therapy
- From:
Chinese Journal of Lung Cancer
2024;27(8):593-604
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer accounts for the highest proportion of cancer deaths in the world and poses a great threat to human health.About 30％to 40％of non-small cell lung cancer(NSCLC)is caused by point mutations,exon insertion and exon deletion of the epidermal growth factor receptor(EGFR).In addition to the common exon 19 deletion mutation and exon 21 L858R mutation,exon 18 G719X mutation,exon 21 L861Qmutation and exon 20 S768I mutation are the most important rare mutations.At present,the diagnostic methods for major rare mutations are mainly next-generation sequenc-ing(NGS),digital polymerase chain reaction(dPCR),droplet digital PCR(ddPCR),etc.Regarding the targeted therapy of G719X/L861Q/S768I mutant NSCLC,the first generation EGFR-tyrosine kinase inhibitors(TKIs)have poor efficacy,while the second and third generation EGFR-TKIs have similar efficacy.The novel third generation EGFR-TKIs and combina-tion therapy show a good therapeutic prospect.This article summarized the progress in the diagnosis and targeted therapy of G719X/L861Q/S768I mutant NSCLC,so as to provide reference for subsequent clinical drug use and research.
